Stock vs Stock Comparison

Can-Fite BioPharma Ltd. vs Johnson & Johnson

JNJ wins the Tale of the Tape 8–1.

CANF
JNJ$223.24

🏆 Tale of the Tape

18
CANFJNJ
-2426.7%Profitability (Net Margin)28.5%
Valuation (P/E)26.1x
-115.9%Efficiency (ROIC)18.3%
2/9Health (Piotroski F)4/9
Safety (Altman Z)4.0
-39.9%Growth (Rev YoY)6.0%
Risk (Sharpe 1Y)2.69
0.70xBalance Sheet (D/E)1.44x
FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCANFJNJ
Market Cap$542.4B
P/E Ratio26.1x
Forward P/E17.7x
P/B6.68x
Dividend Yield2.38%
Beta0.26

Quantitative Metrics

MetricCANFJNJ
DCF Fair Value$134.24
DCF Upside-43.6%
Piotroski F2/94/9
Altman Z3.97
Beneish M-2.27
FCF Yield3.25%
Net Debt/EBITDA0.5x
ROIC-115.9%18.3%
WACC7.7%
ROIC – WACC10.5pp
Gross Margin67.9%
Net Margin-2426.7%28.5%
Rev Growth YoY-39.9%6.0%
Sharpe (1Y)2.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%

CANF Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

CANF found in:

EWX0.07%
SPEM0.01%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CANF vs JNJ: Head-to-Head Analysis

Can-Fite BioPharma Ltd. (CANF) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CANF generates a return on invested capital (ROIC) of -115.9% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

CANF appears in 2 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CANF or JNJ?

Our quantitative analysis compares CANF and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CANF and JNJ correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.